GlassScriptPhysician profile
Antonio Beltran
NPI 1811940596
$51,477.12
in general payments reported to CMS, 2019-2025
19 companies · $14K in 2025
The $14K reported for 2025 was more than what 95% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $229 · 2021: $13K · 2022: $16K · 2023: $33.37 · 2024: $8,294 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Travel and Lodging: $4,398 · Food and Beverage: $431 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,000.00 |
| Travel and Lodging | $4,397.59 |
| Food and Beverage | $431.48 |
| Education | $129.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uromedica, Incorporated | $42,466.59 | 2020-2025 | Proact |
| Intuitive Surgical, INC. | $7,749.31 | 2021 | |
| Axonics, INC. | $238.52 | 2021-2022 | |
| Teleflex LLC | $179.95 | 2024-2025 | Urolift, Barrigel |
| Neotract INC. | $144.68 | 2020 | |
| Inari Medical, INC. | $142.00 | 2019 | |
| Boston Scientific Corporation | $137.66 | 2020-2025 | Spaceoar Vue System - 10ml, Advantage System |
| Janssen Biotech, INC. | $94.00 | 2024 | Erleada |
| Procept Biorobotics Corporation | $62.35 | 2024 | Aquabeam System |
| Astrazeneca Pharmaceuticals LP | $49.12 | 2024-2025 | Imfinzi, Tagrisso |
| Coloplast Corp | $35.94 | 2022-2023 | Speedicath |
| Agiliti Surgical, INC. | $33.24 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $25.04 | 2024 | Bard Silicone Uretero-Intestinal Anastomosis Urinary Diversion Stent |
| Glaxosmithkline, LLC. | $24.07 | 2019 | |
| Cook Medical LLC | $22.13 | 2024 | S~Curve |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $19.05 | 2023 | Soltive |
| Sumitomo Pharma America, INC. | $18.59 | 2024 | Orgovyx |
| Astellas Pharma US INC | $18.17 | 2020 | |
| Abbvie INC. | $16.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Beltran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.